|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Michele Garufi||Co-Founder, Chairman & CEO||501,97k||N/D||1954|
|Ms. Sandrine Gestin||VP of Fin.||N/D||N/D||1967|
|Ms. Emmanuelle Pierry||Gen. Counsel & Head of Legal||N/D||N/D||1969|
|Dr. Gavin Spencer||Exec. VP, Chief Bus. Officer & Head of Corp. Devel.||N/D||N/D||1970|
|Dr. Tomas Navratil Ph.D.||Exec. VP and Head of R&D||N/D||N/D||1977|
Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.
L'ISS Governance QualityScore di Nicox S.A. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.